Pramlintide
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
AstraZeneca · Phase 2 · Completed · Enrollment 636
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo-P + Placebo-M | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcg + Placebo-M | n/r | n/r | n/r | n/r |
| Placebo-P + Metreleptin 5.0 mg | n/r | n/r | n/r | n/r |
| Pramlintide 180 mcg + Metreleptin 2.5 mg | n/r | n/r | n/r | n/r |
| Pramlintide 180 mcg + Metreleptin 5.0 mg | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 1.25 mg | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 2.5 mg | n/r | n/r | n/r | n/r |
| Pramlintide 360 mcg + Metreleptin 5.0 mg | n/r | n/r | n/r | n/r |
Not shown
- Placebo-P + Placebo-M: endpoint not reported
- Pramlintide 360 mcg + Placebo-M: endpoint not reported
- Placebo-P + Metreleptin 5.0 mg: endpoint not reported
- Pramlintide 180 mcg + Metreleptin 2.5 mg: endpoint not reported
- Pramlintide 180 mcg + Metreleptin 5.0 mg: endpoint not reported
- Pramlintide 360 mcg + Metreleptin 1.25 mg: endpoint not reported
- Pramlintide 360 mcg + Metreleptin 2.5 mg: endpoint not reported
- Pramlintide 360 mcg + Metreleptin 5.0 mg: endpoint not reported